News from AHA 2024: PHARM-HF A&F Study, Audit and Feedback

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Matters
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Heart Matters
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD

Audit and feedback strategy for pharmacists improves HF care